Union européenne - français - EMA (European Medicines Agency)

janssen-cilag international nv - guselkumab - psoriasis - immunosuppresseurs - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.

Union européenne - français - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psoriasis - immunosuppresseurs - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Union européenne - français - EMA (European Medicines Agency)

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - immunosuppresseurs - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

Canada - français - Health Canada

abbvie corporation - upadacitinib - comprimé (à libération prolongée) - 15mg - upadacitinib 15mg - disease-modifying antirheumatic agents

Canada - français - Health Canada

abbvie corporation - upadacitinib - comprimé (à libération prolongée) - 30mg - upadacitinib 30mg - disease-modifying antirheumatic agents

Canada - français - Health Canada

abbvie corporation - upadacitinib - comprimé (à libération prolongée) - 45mg - upadacitinib 45mg

Canada - français - Health Canada

pfizer canada ulc - tofacitinib (citrate de tofacitinib) - comprimé - 5mg - tofacitinib (citrate de tofacitinib) 5mg - disease-modifying antirheumatic agents

Canada - français - Health Canada

pfizer canada ulc - tofacitinib (citrate de tofacitinib) - comprimé (à libération prolongée) - 11mg - tofacitinib (citrate de tofacitinib) 11mg - disease-modifying antirheumatic agents

Canada - français - Health Canada

pfizer canada ulc - tofacitinib (citrate de tofacitinib) - comprimé - 10mg - tofacitinib (citrate de tofacitinib) 10mg - disease-modifying antirheumatic agents

Canada - français - Health Canada

pharmascience inc - tofacitinib (citrate de tofacitinib) - comprimé - 5mg - tofacitinib (citrate de tofacitinib) 5mg